Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey W Krystal

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Cancer Biology & Therapy|October 12, 2010
Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737Geoffrey W Krystal
Cancer Biology & Therapy|December 3, 2005
Receptor tyrosine kinase mutations: molecular indicators for therapeutic response or signposts marking important signaling pathways?Geoffrey W Krystal
Leukemia Research|March 24, 2004
Imatinib mesylate (STI571) for myeloid malignancies other than CMLGeoffrey W Krystal
Molecular Cancer Therapeutics|July 5, 2006
Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cellsJulie Litz, Geoffrey W Krystal
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2010
Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell linesHaishan Xu, Geoffrey W Krystal
The New England Journal of Medicine|May 25, 2017
Auer RodsSarah W Gordon, Geoffrey W Krystal
Clinical Lung Cancer|December 10, 2003
Role of small-molecule kit receptor tyrosine kinase inhibitors in the treatment of small-cell lung cancerKatherine P Lloyd, Geoffrey W Krystal
Molecular Cancer Therapeutics|December 17, 2002
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapyGeoffrey W Krystal, Geoffrey Sulanke, Julie Litz
Molecular Cancer Therapeutics|May 8, 2012
Early FDG/PET scanning as a pharmacodynamic marker of anti-EGFR antibody activity in colorectal cancerGeoffrey W Krystal, Erin Alesi, James L Tatum
Molecular Cancer Therapeutics|April 18, 2009
Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737Paula Hauck, Bo H Chao, Julie Litz, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Cancer Biology & Therapy|October 12, 2010
Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737Geoffrey W Krystal
Cancer Biology & Therapy|December 3, 2005
Receptor tyrosine kinase mutations: molecular indicators for therapeutic response or signposts marking important signaling pathways?Geoffrey W Krystal
Leukemia Research|March 24, 2004
Imatinib mesylate (STI571) for myeloid malignancies other than CMLGeoffrey W Krystal
Molecular Cancer Therapeutics|July 5, 2006
Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cellsJulie Litz, Geoffrey W Krystal
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2010
Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell linesHaishan Xu, Geoffrey W Krystal
The New England Journal of Medicine|May 25, 2017
Auer RodsSarah W Gordon, Geoffrey W Krystal
Clinical Lung Cancer|December 10, 2003
Role of small-molecule kit receptor tyrosine kinase inhibitors in the treatment of small-cell lung cancerKatherine P Lloyd, Geoffrey W Krystal
Molecular Cancer Therapeutics|December 17, 2002
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapyGeoffrey W Krystal, Geoffrey Sulanke, Julie Litz
Molecular Cancer Therapeutics|May 8, 2012
Early FDG/PET scanning as a pharmacodynamic marker of anti-EGFR antibody activity in colorectal cancerGeoffrey W Krystal, Erin Alesi, James L Tatum
Molecular Cancer Therapeutics|April 18, 2009
Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737Paula Hauck, Bo H Chao, Julie Litz, et al.
Pageof 2